Chimeric peptides for antisense delivery
Inventors
Pentelute, Bradley L. • Fadzen, Colin M. • Holden, Rebecca L. • Wolfe, Justin M. • Choo, Zi-Ning • Yao, Monica • Hanson, Gunnar J.
Assignees
Massachusetts Institute of Technology • Sarepta Therapeutics Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates, the chimeric peptides and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide. The oligoarginine peptide comprises the sequence [(RYzR)x] (SEQ ID NOs: 15-18), wherein R is arginine, Y is independently selected from aminohexanoic acid (X) or β-alanine (B). Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide described herein.
Core Innovation
The invention is a chimeric peptide–oligonucleotide conjugate, or a pharmaceutically acceptable salt thereof, in which an oligonucleotide is linked to multiple cell-penetrating peptides. The conjugate includes at least one amphipathic peptide and at least one oligoarginine peptide comprising a repeating arginine-containing sequence. The conjugate encompasses defined variations in linkers, terminal groups, oligonucleotides, and numbers of covalently linked peptides.
The disclosure indicates that chimeric conjugates improve exon-skipping readout compared with unconjugated PMO and single-cell-penetrating-peptide conjugates. Reported findings show that activity depends on covalent linkage, peptide identity, and peptide order, wherein separate administration of peptide conjugates fails to reproduce the benefit. Uptake studies implicate endocytosis, indicating distinct functional contributions of the respective peptides to cellular internalization and downstream activity.
Claims Coverage
The relevant claims identify one independent claim, claim 1, comprising four inventive features covering a Formula I chimeric peptide–oligonucleotide conjugate or pharmaceutically acceptable salt thereof.
Chimeric peptide–oligonucleotide conjugate
Claim 1 covers a Formula I conjugate, or a pharmaceutically acceptable salt thereof, comprising an oligonucleotide linked to 2, 3, 4, or 5 covalently linked cell-penetrating peptides.
Combination of amphipathic and oligoarginine peptides
At least one of the cell-penetrating peptides is an amphipathic peptide and at least one is an oligoarginine peptide.
Specified oligoarginine peptide sequence
The oligoarginine peptide comprises a repeating arginine-containing sequence [procedural detail omitted for safety] with defined spacer residues.
Covalent linkage of cell-penetrating peptides
The claim specifies two, three, four, or five cell-penetrating peptides covalently linked at the peptide termini.
The independent claim centers on a Formula I peptide–oligonucleotide conjugate or salt thereof, specifying multiple covalently linked cell-penetrating peptides combining amphipathic and oligoarginine peptides.
Stated Advantages
The disclosed chimeric conjugates improve exon-skipping and eGFP readout compared with unconjugated PMO and single-cell-penetrating-peptide conjugates, showing activity greater than additive expectations.
A PMO–penetratin–Bpep conjugate provides over 20-fold improvement versus PMO and about 70-fold fluorescence over untreated cells.
Documented Applications
Therapeutic applications include the treatment of neuromuscular and muscle diseases, including Duchenne muscular dystrophy.
Therapeutic applications include the treatment of viral infections and bacterial infections.
The conjugates are documented for use in cellular exon-skipping assays [procedural detail omitted for safety].
Interested in licensing this patent?